Related Experiment Video
Updated: Jun 16, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Tailored cancer outcome prediction and informed consent
Robert Patrick1, Laura Buccini, Michael W Kattan
1Department of Hospital Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195,USA. patricr2@ccf.org
Seminars in Oncology
|February 23, 2010
Summary
Physicians should disclose cancer treatment outcome disparities between institutions to patients. Tailored statistical models can present this complex data, preserving patient autonomy and improving informed consent for cancer care.
Area of Science:
- Oncology
- Medical Ethics
- Health Informatics
Background:
- Established clinically relevant disparities exist in cancer treatment outcomes across different institutions.
- Physicians may have an ethical duty to disclose these outcome disparities during the informed consent process.
Purpose of the Study:
- Advocate for the disclosure of institution-specific cancer treatment outcomes to uphold patient autonomy.
- Propose a framework for presenting this information using individualized statistical prediction models.
Main Methods:
- Describe a hypothetical system for collecting and distributing cancer outcome data, drawing parallels with the United Network for Organ Sharing.
- Articulate the scientific and logistical feasibility of developing accurate and equitable patient-specific prediction models.
Main Results:
- The proposed system aims to provide a transparent and equitable method for sharing cancer outcome data.
- Accurate and fair prediction models are deemed scientifically and logistically achievable.
Conclusions:
- Disclosure of institution-specific cancer outcomes, framed by personalized statistical models, is essential for patient autonomy.
- Careful system design and oversight are necessary to mitigate potential negative consequences of data dissemination.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:24Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...